Anti-angiogenic compositions and methods of use

TL;DR: In this paper, the authors present methods for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

TL;DR: In this paper, the degradation times of polyhydroxyalkanoates are controlled under physiological conditions, and the degradation rates are controlled with less than one year under certain physiological conditions.

TL;DR: In this paper, a coronary stent implantable medical device is defined as a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.

TL;DR: In this paper, a method for a coating an implantable device or prosthesis is described, which includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed therein.

TL;DR: In this paper, the authors describe a protein or a pharmaceutically acceptable salt thereof, which has a molecular weight of 10,000-30,000 Dalton and an isoelectric point greater than 9.5.

TL;DR: The procedure has reached such a level of success that randomized studies comparing angioplasty to either bypass surgery or medical treatment are now, appropriately, underway.

TL;DR: In this paper, the combination of low density lipoproteins with active and effective lipophilic peptide or other lipophilicity immunomodulators, antigens or vaccines to carry the same to macrophage specific targeted receptor mediated endocytosis sites in a living system for treatment of cancer, infection hyper immune related diseases or deficiences, or to enhance vaccine induction of immunity.